Registry for patients with neuromuscular disorders in Switzerland

Swiss Registry for Neuromuscular Disorders (Swiss-Reg-NMD)

Observational University of Bern · NCT05102916

This study is creating a database to help people in Switzerland with neuromuscular disorders, like DMD and SMA, get access to new treatments and participate in clinical trials.

Quick facts

Study typeObservational
Enrollment2000 (estimated)
Ages0 Years and up
SexAll
SponsorUniversity of Bern Academic / other
Locations19 sites (Aarau, Canton of Aargau and 18 other locations)
Trial IDNCT05102916 on ClinicalTrials.gov

What this trial studies

The Swiss Registry for Neuromuscular Disorders collects medical information from individuals diagnosed with conditions such as Duchenne-Becker Muscular Dystrophy (DMD/BMD), Spinal Muscular Atrophy (SMA), and LAMA2-related muscular dystrophy. Established in 2008, this registry aims to facilitate access to new therapies for Swiss patients by creating a centralized database that supports participation in therapeutic trials. The registry is managed by specialized physicians across Switzerland and has been adapted to meet evolving legal and patient needs. It aims to establish a representative cohort and provide valuable epidemiological data on these rare diseases.

Who should consider this trial

Good fit: Ideal candidates include children, adolescents, and adults diagnosed with neuromuscular disorders who are living or receiving treatment in Switzerland.

Not a fit: Patients who do not have a confirmed diagnosis of a neuromuscular disorder may not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could enhance access to innovative treatments for patients with neuromuscular disorders.

How similar studies have performed: Other registries for rare diseases have shown success in improving patient access to therapies and facilitating research, indicating a positive precedent for this approach.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Children, adolescents and adults diagnosed with a NMD
* Who are living or treated for a NMD in Switzerland, and
* Who gave informed consent

Exclusion Criteria:

* None if diagnosis is confirmed, whenever possible, by genetic testing, or at least by biopsy and/or electroneuromyography, according to international standards for the diagnosis of the given NMD.

Where this trial is running

Aarau, Canton of Aargau and 18 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions SMADMDBMDIMDCongenital Muscular DystrophyLAMA2COL-6CMD
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.